ホーム › 慢性リンパ性白血病 › ノースカロライナ › Durham
Durham、NCにおける慢性リンパ性白血病の臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、慢性リンパ性白血病に関する27件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
被験者募集中第3相
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
被験者募集中第3相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
- University of North Carolina-Hillsborough Campus, Hillsborough · 13マイル先
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
被験者募集中第3相
- University of North Carolina At Chapel Hill, Chapel Hill · 10マイル先
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
被験者募集中第3相
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
被験者募集中第3相
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · 10マイル先
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
被験者募集中第2相
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
被験者募集中第2相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
被験者募集中第1/2相
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10マイル先
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10マイル先
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
被験者募集中第2相
- Research Site, Durham
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
被験者募集中第1相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
被験者募集中
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10マイル先
Registry of Older Patients With Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Duke University Medical Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
被験者募集中第1相
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
被験者募集中第2相
- University of North Carolina /ID# 233313, Chapel Hill · 10マイル先
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
被験者募集中第2相
- The University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
被験者募集中第1相
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
被験者募集中第2相
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
被験者募集中第1相
- Duke University, Durham
他の都市における慢性リンパ性白血病の試験
- Boston, MA31件の研究
- Columbus, OH28件の研究
- Washington, DC22件の研究
- Seattle, WA20件の研究
- Rochester, MN19件の研究
- New York City, NY18件の研究
- Houston, TX17件の研究
- Baldwin Park, CA16件の研究
- Milwaukee, WI15件の研究
- Chicago, IL14件の研究
- Cincinnati, OH14件の研究
- Nashville, TN13件の研究
Durhamにおける他の研究
- 乳がん63件の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 多発性骨髄腫37件の研究
- 転移性癌33件の研究
- 急性骨髄性白血病33件の研究
- 肺がん32件の研究
- 前立腺がん32件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 心不全26件の研究
- 膵臓がん24件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。